LOVELAND, Colorado, E.I. Medical Imaging (EIMI), a worldwide leader in portable ultrasound systems for veterinary use announced today they have received ISO 9001:2008 Certification.  

Drug-making plant blooms
Approval of a ‘biologic’ manufactured in plant cells may pave the way for similar products.
BY AMY MAXMEN

It was midnight when an anxious Ari Zimran finally got the phone call for which he had been waiting. The news couldn’t have been better: the drug he had worked on for nearly a decade had just been approved by the US Food and Drug Administration (FDA). 

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ:CLVS) today reported financial results for the first quarter 2012, and provided an update on the progress of its clinical development programs and expected milestones for the rest of the year.  

LONGMONT, CO May 7th, 2012. Acertara Acoustic Laboratories, the world’s only independent ISO/IEC 17025:2005 accredited medical ultrasound acoustic measurement and testing laboratory, announces that its research and development team has been awarded three new United States patents in as many weeks. US patents 8,159,900, 8,164,976, and 8,169,853, authored by John Timms, James Gessert, Matthew Fitzgibbons, and G. Wayne Moore are related to novel technology designed to validate the performance of diagnostic ultrasound systems. The R&D team members of Acertara have been awarded more than 30 United States patents. 

CENTENNIAL, Colo., May 2, 2012 /PRNewswire/ -- Cochlear Americas, the world's leading implantable hearing solutions company, announced today the launch of its smartphone support application for Nucleus® Cochlear Implant recipients. The Nucleus Support App joins the Baha® Support App as part of Cochlear's mobile support initiative, which provides information and assistance to recipients whenever and wherever they need it. 

INDUSTRY VETERAN BRINGS SALES EXPERTISE TO ALLOSOURCE’S GROWING DISTRIBUTION NETWORK 

BOULDER, CO, April 26, 2012 – MiRagen Therapeutics, Inc., a biopharmaceutical company developing innovative microRNA (miRNA)-based therapeutics primarily for the treatment of patients who suffer from cardiovascular and muscle disease, announced today that scientific results published in the journal Cell reveal the central role of the heart in whole-body metabolism.   

BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) today announced that Ron Squarer has been appointed Chief Executive Officer, effective immediately. Mr. Squarer has also been named to the Array Board of Directors.  

DENVER--(BUSINESS WIRE)--Accelr8 Technology Corporation (Amex: AXK) announced today that an investment group formed by Jack Schuler, John Patience, and Larry Mehren will invest a total of up to $35 million in Accelr8’s common stock. The purpose is to complete the product development and market introduction of Accelr8’s BACcel™ culture-free, diagnostic system for same-shift identification and antibiotic resistance testing of bacterial and fungal pathogens.  

LEADING DEVELOPER OF MOLECULAR-BASED TESTS FOR ONCOLOGY NAMES
BURNS MARKETING AS ITS AGENCY OF RECORD